Metabolic Brain Disease

Papers
(The H4-Index of Metabolic Brain Disease is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Emerging role of non‐coding RNA in health and disease104
Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside80
Role of metals in Alzheimer’s disease76
Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach71
Crossing the blood-brain barrier with AAV vectors52
Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease50
Cellular and molecular pathophysiology in the progression of Parkinson’s disease47
PTZ kindling model for epileptogenesis, refractory epilepsy, and associated comorbidities: relevance and reliability46
Clinical features, pathogenesis, and management of stroke-like episodes due to MELAS41
Neuroprotective potential of Malva neglecta is mediated via down-regulation of cholinesterase and modulation of oxidative stress markers36
Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain36
Cognitive impairment caused by hypoxia: from clinical evidences to molecular mechanisms35
A novel antagonist of TRPM2 and TRPV4 channels: Carvacrol33
Cannabidiol induces antidepressant and anxiolytic‐like effects in experimental type-1 diabetic animals by multiple sites of action32
Methods used for the measurement of blood-brain barrier integrity31
Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppress30
The role of syringic acid as a neuroprotective agent for neurodegenerative disorders and future expectations30
Bone marrow mesenchymal stem cell-derived exosomes carrying long noncoding RNA ZFAS1 alleviate oxidative stress and inflammation in ischemic stroke by inhibiting microRNA-15a-5p29
Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment29
Neuroprotective effects of 18β-glycyrrhetinic acid against bisphenol A-induced neurotoxicity in rats: involvement of neuronal apoptosis, endoplasmic reticulum stress and JAK1/STAT1 signaling pathway29
Profiles of urine and blood metabolomics in autism spectrum disorders29
Protective mechanism of Syringic acid in an experimental model of Parkinson’s disease28
Capsaicin induces redox imbalance and ferroptosis through ACSL4/GPx4 signaling pathways in U87-MG and U251 glioblastoma cells26
Targeting inflammation: a potential approach for the treatment of depression26
A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis26
MiRNA-34c-5p protects against cerebral ischemia/reperfusion injury: involvement of anti-apoptotic and anti-inflammatory activities25
Reactive gliosis in Alzheimer’s disease: a crucial role for cognitive impairment and memory loss25
Metabolic disorder in Alzheimer’s disease25
Hesperetin ameliorates diabetes-associated anxiety and depression-like behaviors in rats via activating Nrf2/ARE pathway25
Treatment trials in Niemann-Pick type C disease25
0.037137031555176